Imbalance in the response of pre- and post-synaptic components to amyloidopathy.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 10 2019
Historique:
received: 10 05 2019
accepted: 12 09 2019
entrez: 18 10 2019
pubmed: 18 10 2019
medline: 12 11 2020
Statut: epublish

Résumé

Alzheimer's disease (AD)-associated synaptic dysfunction drives the progression of pathology from its earliest stages. Amyloid β (Aβ) species, both soluble and in plaque deposits, have been causally related to the progressive, structural and functional impairments observed in AD. It is, however, still unclear how Aβ plaques develop over time and how they progressively affect local synapse density and turnover. Here we observed, in a mouse model of AD, that Aβ plaques grow faster in the earlier stages of the disease and if their initial area is >500 µm

Identifiants

pubmed: 31619689
doi: 10.1038/s41598-019-50781-1
pii: 10.1038/s41598-019-50781-1
pmc: PMC6795896
doi:

Substances chimiques

APP protein, human 0
Amyloid beta-Peptides 0
Amyloid beta-Protein Precursor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14837

Subventions

Organisme : Medical Research Council
ID : G1100623
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14127
Pays : United Kingdom

Références

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1514-23
pubmed: 23542382
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):4012-7
pubmed: 19228947
Nature. 2008 Feb 7;451(7179):720-4
pubmed: 18256671
Science. 2016 May 6;352(6286):712-716
pubmed: 27033548
J Neuropathol Exp Neurol. 2002 Sep;61(9):797-805
pubmed: 12230326
J Neurosci. 2015 Jul 15;35(28):10325-30
pubmed: 26180207
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Neurobiol Aging. 2011 Nov;32(11):2109.e1-14
pubmed: 21794952
J Neurosci. 2006 Mar 15;26(11):3021-9
pubmed: 16540580
Life Sci Alliance. 2018 Jun 14;1(3):e201800028
pubmed: 30456353
J Neurosci. 2000 Jun 1;20(11):4050-8
pubmed: 10818140
Neuron. 2010 Dec 22;68(6):1067-81
pubmed: 21172610
Science. 1991 Oct 4;254(5028):97-9
pubmed: 1925564
Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20816-21
pubmed: 21076037
PLoS One. 2016 Nov 4;11(11):e0165144
pubmed: 27814403
Mol Psychiatry. 2014 Aug;19(8):937-46
pubmed: 24061497
Front Neurosci. 2019 Jul 23;13:735
pubmed: 31396031
Acta Neuropathol Commun. 2014 Mar 28;2:30
pubmed: 24678659
J Neurosci. 2011 Jan 12;31(2):624-9
pubmed: 21228171
PLoS Med. 2017 Mar 28;14(3):e1002270
pubmed: 28350801
J Neurosci. 2009 Aug 26;29(34):10627-37
pubmed: 19710315
Acta Neuropathol Commun. 2019 May 21;7(1):82
pubmed: 31113487
J Exp Med. 2016 May 2;213(5):667-75
pubmed: 27091843
Front Aging Neurosci. 2016 Nov 10;8:267
pubmed: 27891091
Neuron. 2004 Sep 30;44(1):181-93
pubmed: 15450169
J Neuropathol Exp Neurol. 1997 Aug;56(8):933-44
pubmed: 9258263
Neuron. 2016 May 18;90(4):724-39
pubmed: 27196974
Nat Commun. 2015 Jan 29;6:6176
pubmed: 25630253
Nat Genet. 1992 Aug;1(5):345-7
pubmed: 1302033
J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):982-994
pubmed: 28844070
J Neurosci. 2010 Jun 9;30(23):7793-803
pubmed: 20534828
J Clin Invest. 2002 Nov;110(10):1375-81
pubmed: 12438432
EMBO J. 2017 Sep 1;36(17):2473-2487
pubmed: 28768718
Acta Neuropathol. 2013 Aug;126(2):179-88
pubmed: 23775142
J Neurocytol. 2004 May;33(3):377-87
pubmed: 15475691
J Neurosci. 2005 Aug 3;25(31):7278-87
pubmed: 16079410
Neuropharmacology. 2010 Sep-Oct;59(4-5):243-67
pubmed: 20167227
J Comp Neurol. 2007 Jan 10;500(2):311-21
pubmed: 17111375
J Neurosci. 2006 Oct 4;26(40):10129-40
pubmed: 17021169
Sci Rep. 2011;1:19
pubmed: 22355538
Cell Rep. 2017 Mar 28;18(13):3063-3068
pubmed: 28355559
PLoS One. 2010 Nov 16;5(11):e15477
pubmed: 21103384
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3228-33
pubmed: 10077666
Neuron. 2006 Mar 16;49(6):861-75
pubmed: 16543134
Neuron. 2012 Dec 6;76(5):908-20
pubmed: 23217740
Science. 2013 Sep 20;341(6152):1399-404
pubmed: 24052308
Nature. 2002 Dec 19-26;420(6917):788-94
pubmed: 12490942
Front Neurol. 2013 Feb 13;4:9
pubmed: 23407382
J Neurosci. 2005 Oct 26;25(43):9989-99
pubmed: 16251447
Cell Rep. 2018 Apr 24;23(4):1060-1071
pubmed: 29694885
J Neurosci. 2013 Aug 7;33(32):12997-3009
pubmed: 23926255
Neurobiol Aging. 2006 Oct;27(10):1372-84
pubmed: 16289476
Nature. 2006 Jun 22;441(7096):979-83
pubmed: 16791195
Nat Commun. 2017 Nov 10;8(1):1403
pubmed: 29123083

Auteurs

Terri-Leigh Stephen (TL)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Department of Gerontology, University of Southern California, Los Angeles, California, 90089, USA.

Francesco Tamagnini (F)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
School of Pharmacy, University of Reading, Whiteknights Campus, Hopkins Building, Reading, RG6 6LA, UK.
Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Hatherly Laboratories, University of Exeter, Exeter, EX4 4PS, UK.

Judith Piegsa (J)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Hatherly Laboratories, University of Exeter, Exeter, EX4 4PS, UK.

Katherine Sung (K)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Joshua Harvey (J)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Alice Oliver-Evans (A)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Tracey K Murray (TK)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Zeshan Ahmed (Z)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Michael L Hutton (ML)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Andrew Randall (A)

Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Hatherly Laboratories, University of Exeter, Exeter, EX4 4PS, UK.

Michael J O'Neill (MJ)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
AbbVie Deutschland GmbH & Co. K.G., Ludwigshafen, Germany.

Johanna S Jackson (JS)

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK. johanna.jackson@imperial.ac.uk.
UK Dementia Research Institute at Imperial College, Department of Brain Sciences, Imperial College London, London, UK. johanna.jackson@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH